Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) shares traded 10.61% higher at $2.19 on Wall Street last session.
LXRX stock price is now -3.12% away from the 50-day moving average and 25.91% away from the 200-day moving average. The market capitalization of the company currently stands at $536.40M.
With the price target of $3, Jefferies recently initiated with Hold rating for Lexicon Pharmaceuticals Inc (NASDAQ: LXRX). On August 12, 2022, Piper Sandler recently initiated its ‘Overweight’ rating on the stock quoting a target price of $10, while ‘JP Morgan’ rates the stock as ‘Neutral’
In other news, COATS LONNEL, Chief Executive Officer bought 90,000 shares of the company’s stock on Nov 16 ’23. The stock was bought for $94,797 at an average price of $1.05. Upon completion of the transaction, the Chief Executive Officer now directly owns 914,359 shares in the company, valued at $2.0 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 10 ’23, Chief Executive Officer COATS LONNEL bought 10,000 shares of the business’s stock. A total of $10,100 was incurred on buying the stock at an average price of $1.01. This leaves the insider owning 824,359 shares of the company worth $1.81 million. A total of 2.73% of the company’s stock is owned by insiders.
During the past 12 months, Lexicon Pharmaceuticals Inc has had a low of $0.92 and a high of $3.79. As of last week, the company has a debt-to-equity ratio of 1.14, a current ratio of 5.60, and a quick ratio of 5.58. The fifty day moving average price for LXRX is $2.2780 and a two-hundred day moving average price translates $1.7364 for the stock.
The latest earnings results from Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) was released for Dec, 2023. According to the Biotechnology Company, earnings per share came in at -$0.2, beating analysts’ expectations of -$0.22 by 0.02. This compares to -$0.16 EPS in the same period last year. The net profit margin was -14573.20% and return on equity was -167.06% for LXRX. The company reported revenue of $0.7 million for the quarter, compared to $28000.0 a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 2403.57 percent. For the current quarter, analysts expect LXRX to generate $1.37M in revenue.
